Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in inflammation. The company had completed a phase 1 trial of CDX-585, a bispecific ...

Brain tumors are one of most common solid tumor types in kids and teens. And about 72% of the children who are diagnosed with a brain tumor are younger than age 15. Children can get several types ...

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...

CAR-T cells are already used today to treat a number of blood cancers, but solid tumors continue to pose significant challenges for this mode of therapy in terms of both safety and efficacy.

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Elevation Oncology, Inc. ( (ELEV) ) has released its Q3 earnings. Here is a breakdown of the information Elevation Oncology, Inc. presented to ...

Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enrich ...

“Heading into 1Q25, we also believe BPMC could be seen as an attractive target for strategic partnerships, which could boost shares,” JP Morgan writes. With Ayvakit’s launch being a major focus for ...